This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This KCNQ3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 651-679 amino acids from the C-terminal region of human KCNQ3.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
KCNQ3
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 3 (KCNQ3))
KCNQ3 antikoerper, si:ch211-66b9.3 antikoerper, BFNC2 antikoerper, EBN2 antikoerper, KV7.3 antikoerper, potassium voltage-gated channel subfamily Q member 3 antikoerper, potassium voltage-gated channel, KQT-like subfamily, member 3 antikoerper, potassium voltage-gated channel, subfamily Q, member 3 antikoerper, KCNQ3 antikoerper, kcnq3 antikoerper, Kcnq3 antikoerper
Hintergrund
The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and one of two related proteins encoded by the KCNQ2 and KCNQ5 genes, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2).